Garry Arthur Neil
Dr. Garry A. Neil, MD, is a Chief Scientific Officer at Cerecor, Inc., a Chairman at Arena Pharmaceuticals, Inc., a Member at BioMarker Pharmaceuticals, Inc., a Principal at American College of Gastroenterology and a Principal at The FDA Alliance. He is on the Board of Directors at Center For Discovery & Innovation In Parasitic Diseases, FBB Biomed, Inc., Reagan-udall Foundation, University of Medicine & Dentistry of New Jersey and Manufacturers Association of Nigeria.
Dr. Neil was previously employed as an Independent Director by GTx, Inc., a Chief Scientific Officer by Aevi Genomic Medicine, Inc., a Partner by Apple Tree Partners, a Vice President-Science & Technology by Johnson & Johnson, a Group President by Johnson & Johnson Pharmaceutical Research & Development LLC, a Principal by Ludwig Institute for Cancer Research Ltd., a Principal by American College of Physicians, Inc. /Old/, a Principal by Astra LLC, a Vice President-Clinical Research by Astra Merck, Inc., a Principal by Astra Pharmaceuticals LP, a Vice President-Clinical Research by AstraZeneca LP, a Member by Bard's Tale Beer Co. LLC, a Vice President-Research & Development by EMD Pharmaceuticals, Inc., a Vice President-Research & Development by Merck KGaA, a Chairman by Pharmaceutical Research & Manufacturers Association, a Chairman by Pharmaceutical Research & Manufacturers of America, a Vice Chairman by Pharmaceutical Research Corp., a Chairman by PhRMA Foundation, a Chairman by Transcelerate Biopharma, Inc., a Principal by University of Iowa, a Principal by University of Pennsylvania, and a Principal by University of Toronto. He also served on the board at Foundation for the National Institutes of Health, Inc., J. & J. Denholm Ltd. and National Institutes of Health.
He received his undergraduate degree from the University of Saskatchewan and a doctorate degree from the University of Saskatchewan College of Medicine.
|06/10/2021||3,692||Acquisition at $2.28 per share.||8,417|
|12/10/2020||3,599||Acquisition at $2.28 per share.||8,205|
|06/10/2020||1,799||Acquisition at $2.28 per share.||4,101|
|02/03/2020||72,282||Award at $0 per share.||0|